The latest price target for Protara Therapeutics (NASDAQ:TARA) was reported by Guggenheim on December 6, 2024. The analyst firm set a price target for $20.00 expecting TARA to rise to within 12 months (a possible 274.53% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Protara Therapeutics (NASDAQ:TARA) was provided by Guggenheim, and Protara Therapeutics reiterated their buy rating.

There is no last upgrade for Protara Therapeutics

There is no last downgrade for Protara Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protara Therapeutics was filed on December 6, 2024 so you should expect the next rating to be made available sometime around December 6, 2025.

While ratings are subjective and will change, the latest Protara Therapeutics (TARA) rating was a reiterated with a price target of $20.00 to $20.00. The current price Protara Therapeutics (TARA) is trading at is $5.34, which is out of the analyst’s predicted range.